AstraZeneca: Combinations Are Key For GLP-1’s Next Evolutionary Step
Executive Summary
In an interview, company’s diabetes lead exec Topher Brooke weighs in on fixed combinations carrying Bydureon, why Byetta still matters, and how it can compete with a “slew” of GLP-1 competitors.